Concepedia

Author

Pranita D. Tamma

Johns Hopkins UniversityORCID

Also Known As

Ana Sandri, Antibacterial Resistance Leadership Group, Kathryn Dzintars, Matthew Toerper, P. D. Tamma, P. Tamma, P.D. Tamma, Pranita D. Tamma, Pranita D Tamma, Pranita D. Tamma

375

Publications

14.9K

Citations

58

H-Index

87

Concepts

All Affiliations

Johns Hopkins UniversityJohns Hopkins MedicineJohns Hopkins HospitalUniversity of Maryland, BaltimoreUniversity of Pennsylvania
PD

About

Pranita D. Tamma is an author at Johns Hopkins University specializing in medicine, infection control, and antimicrobial resistance.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

25

37

1.7K

2

Health Sciences

13

14

485

3

Public Health

9

9

554

4

Humanities

2

2

78

5

Allergy

1

1

34

Pranita D. Tamma

×

143

Publications

10.3K

Citations

49

H-Index

YearCitations

Association of Adverse Events With Antibiotic Use in Hospitalized Patients

Pranita D. Tamma, Edina Avdic, David X. Li,

JAMA Internal Medicine

2017

723

Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections

Pranita D. Tamma, Emily L. Heil, Julie Ann Justo,

Clinical Infectious Diseases

2024

672

Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections

Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo,

Clinical Infectious Diseases

2023

631

Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and <i>Pseudomonas aeruginosa</i> with Difficult-to-Treat Resistance (DTR-<i>P. aeruginosa</i>)

Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo,

Clinical Infectious Diseases

2022

458

Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and <i>Pseudomonas aeruginosa</i> with Difficult-to-Treat Resistance (DTR-<i>P. aeruginosa</i>)

Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo,

Clinical Infectious Diseases

2020

405

Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant <i>Enterobacteriaceae</i> Bacteremia

Pranita D. Tamma, Katherine E Goodman, Anthony Harris,

Clinical Infectious Diseases

2016

388

Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and<i>Pseudomonas aeruginosa</i>with Difficult-to-Treat Resistance (DTR-<i>P. aeruginosa</i>)

Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo,

Clinical Infectious Diseases

2021

376

Carbapenem Therapy Is Associated With Improved Survival Compared With Piperacillin-Tazobactam for Patients With Extended-Spectrum β-Lactamase Bacteremia

Pranita D. Tamma, Jennifer Han, Clare Rock,

Clinical Infectious Diseases

2015

318

Safety of influenza vaccination during pregnancy

Pranita D. Tamma, Kevin A. Ault, Carlos del Rı́o,

American Journal of Obstetrics and Gynecology

2009

261

Multicenter Initial Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2

Kathleen Chiotos, Molly Hayes, David W. Kimberlin,

Journal of the Pediatric Infectious Diseases Society

2020

187

Page 1